About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Diabetes Clinical Trials in Nashville | 535 Studies | Clareo Health

Clinical Trials DiabetesNashville

Diabetes Clinical Trials in Nashville

Find 535 clinical trials for diabetes near Nashville, Tennessee. Connect with research centers in your area.

All Diabetes trials nationwide All trials in Nashville

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 461-480 of 535 trials

TERMINATEDNA7.5 miles

Effect of Platelet Concentrate in Treatment of Diabetic Ulcers

NCT00215735

Autologous platelet concentrate will enhance the rate of healing of chronic diabetic wounds

Harvest TechnologiesStarted Jun 2004

Fayetteville, Alaska, United States • Orlando, Florida, United States • St. Petersburg, Florida, United States +6 more locations

COMPLETEDPhase 260 miles

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT00901979

This study will assess the effect of LCQ when added to metformin.

Type 2 Diabetes Mellitus

Novartis Pharmaceuticals693 participantsStarted Apr 2009

Mesa, Arizona, United States • Mesa, Arizona, United States • Little Rock, Arkansas, United States +64 more locations

Diabetes Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPhase 390 miles

A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT00246987

To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.

Diabetes, Type 2

Bristol-Myers Squibb341 participantsStarted Jun 2003

Anniston, Alabama, United States • Birmingham, Alabama, United States • Haleyville, Alabama, United States +127 more locations

COMPLETED100 miles

Screening for Early Evidence of Diabetes

NCT00614783

This is a pivotal study to determine the accuracy of a new device (SCOUT) in screening persons for pre-diabetes or diabetes. SCOUT will be compared to the standard screening test (Fasting Plasma Glucose), using the Oral Glucose Tolerance Test as the reference standard. SCOUT uses a rapid, noninvasive, light-based technology to measure the concentration of chemicals in the skin called advanced glycation endproducts (AGEs). Several studies have demonstrated that AGEs accumulate in skin faster in individuals with poor control of blood sugar. Persons will be eligible for the study if they are 'at risk' for diabetes based on their age and other risk factors as defined by the American Diabetes Association.

Diabetes Mellitus, Type 2

VeraLight, Inc.3,478 participantsStarted May 2007

Huntsville, Alabama, United States • San Diego, California, United States • San Diego, California, United States +12 more locations

COMPLETEDPhase 2155 miles

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

NCT00889486

The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.

GastroparesisDiabetes Mellitus

Tranzyme, Inc.92 participantsStarted Apr 2009

Long Beach, California, United States • Los Angeles, California, United States • San Francisco, California, United States +20 more locations

COMPLETED155 miles

Follow-Up Study for Exubera

NCT00734591

In studies of Exubera in persons with diabetes, lung cancer occurred in a few more people who were taking Exubera than in people who were taking other diabetes medicines. All subjects diagnosed with lung cancer had a history of smoking and the number of lung cancer cases observed fell within the expected range based on population-based data. There is currently not enough information to determine if any of the observed lung cancer cases were related to Exubera use, therefore, the study is being conducted to further investigate whether Exubera use makes the appearance of lung cancer more likely.

Diabetes Mellitus

Pfizer7,439 participantsStarted Aug 2008

Bay Minette, Alabama, United States • Graysville, Alabama, United States • Pell City, Alabama, United States +318 more locations

COMPLETEDPhase 1160 miles

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

NCT01478399

Primary objective: To compare the pharmacokinetic profile of Glymera (PB1023) Injection after a single dose administered by subcutaneous injection to subjects with normal renal function and impaired renal function. Secondary objectives: To evaluate the safety and tolerability of Glymera (PB1023) Injection administered as a subcutaneous injection in adult subjects with normal renal function and impaired renal function.

Diabetes Mellitus, Type 2

PhaseBio Pharmaceuticals Inc.16 participantsStarted Dec 2011

Saint Paul, Minnesota, United States • Knoxville, Tennessee, United States

COMPLETEDPhase 1160 miles

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

NCT00501462

This is an open-label study that will measure blood levels of different parts of a drug called GKS189075. People participating in this study will receive a single dose of 250mg GSK189075 by mouth. About 20 people with mild to moderate decrease in renal (kidney) function will be asked to participate in this study. They will be compared to about 20 healthy participants who are close to the same age and body size. People participating in this study will stay at a clinical research unit beginning 2 days before they receive their single dose of GSK189075 and will remain there until approximately one day after receiving the study drug. During this study urine will be collected beginning the day before receiving study drug until the day after, just prior to leaving the clinical research unit. Blood samples will also be collected at various times beginning immediately before until 24 hours after receiving the study drug.

Type 2 Diabetes MellitusDiabetes Mellitus, Type 2Renal Insufficiency

GlaxoSmithKline29 participantsStarted Jul 2007

Orlando, Florida, United States • Minneapolis, Minnesota, United States • Knoxville, Tennessee, United States +1 more locations

COMPLETEDPhase 2179 miles

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

NCT01338870

B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.

Diabetes Mellitus, Type 2

Pfizer301 participantsStarted Jun 2011

Little Rock, Arkansas, United States • Roseville, California, United States • Denver, Colorado, United States +39 more locations

COMPLETED183 miles

Evaluation of Low Source of Signal in SCOUT DS

NCT01339637

The overall objective of this study is to increase the number of dark skin tone individuals in the data set and evaluate if this increase in dark skin tone data has an impact on the accuracy of the SCOUT DS Diabetes Risk Score (DRS).

Metabolic SyndromeImpaired Glucose ToleranceGestational Diabetes

VeraLight, Inc.196 participantsStarted Apr 2011

Birmingham, Alabama, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +2 more locations

COMPLETEDPhase 3183 miles

Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

NCT00553787

The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.

ObesityType 2 Diabetes

VIVUS LLC2,487 participantsStarted Nov 2007

Birmingham, Alabama, United States • Ridgefield, Connecticut, United States • New York, New York, United States +3 more locations

UNKNOWNNA215 miles

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease

NCT01792206

The purpose of this research study is to study the effects of paricalcitol on endothelial function and inflammation, cardiovascular risk factors which are associated with patient populations that have Type 2 diabetes and Stage 3 and 4 Chronic Kidney Disease (CKD). Hypothesis 1: The state of CKD is associated with oxidative stress and inflammation and impaired post ischemic endothelium dependent flow mediated vasodilation which may contribute to atherogenesis. Hypothesis 2: The administration of paracalcitol to patients with CKD will suppress oxidative stress and inflammation and improve endothelial function and thus contribute to an anti-atherogenic action.

Type 2 DiabetesChronic Kidney Disease

Scott and White Hospital & Clinic60 participantsStarted Sep 2009

Atlanta, Georgia, United States • New Orleans, Louisiana, United States • Boston, Massachusetts, United States +1 more locations

TERMINATEDPhase 2253 miles

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

NCT00698789

Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.

Type 2 Diabetes

Incyte Corporation48 participantsStarted May 2008

Phoenix, Arizona, United States • Tucson, Arizona, United States • Chula Vista, California, United States +19 more locations

COMPLETEDNA291 miles

Multicenter Worksite Nutrition Study

NCT01224548

The purpose of this study is to study the potential benefits of low fat vegan diet in a randomized, controlled and multi-centered workplace setting, the investigators will enroll participants from 10 worksites of Government Employee Insurance Company (GEICO). After randomization, 5 will be the vegan sites and 5 will be the control sites for 10 month study. The vegan sites will receive low fat vegan diet instructions and weekly group sessions starting from year 1. no intervention is done to the control sites until the week 18 when the identical program will be given. At various time points, health measurements will be give to all participants.

DiabetesOverweight

Physicians Committee for Responsible Medicine292 participantsStarted Oct 2010

Tucson, Arizona, United States • San Diego, California, United States • Lakeland, Florida, United States +7 more locations

COMPLETEDPhase 2475 miles

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00476931

The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic Polyneuropathy

Sangamo Therapeutics91 participantsStarted May 2007

La Jolla, California, United States • Lakewood, California, United States • Lomita, California, United States +17 more locations

TERMINATEDPhase 4697 miles

Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects

NCT01582282

A double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of 2 phases; 1) an 8-week lead-in period during which patients followed a diet judged to be within the acceptable guidelines of the ADA, and 2) a 12-week treatment period, at the beginning of which, Subjects are randomly assigned to 1 of the 3 treatment groups: placebo, 3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil) or 6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil). For 12 weeks, Subjects took Metamucil or the fiber-free placebo BID, just prior to breakfast and dinner. Patients visited the clinic 10 times during the 20-week period at Screening, Weeks -8, -6, -4, 0, Day 3, and Weeks 2, 4, 8 and 12, fasting at least 12 hours prior to each visit where a blood sample was taken (all visits except Week -6 and Day 3) for analysis of fasting serum glucose and lipid levels, and HbA1c. Clinical chemistry, hematology and urinalysis were done at Weeks -8, 0 and 12. The completed 7-day food diaries were reviewed by the study dietician at each visit and discussed with the patient to ensure compliance with the recommended diet and the patients' body weights were recorded

Non-Insulin-dependent Diabetes Mellitus

Procter and Gamble37 participantsStarted May 1988

Miami, Florida, United States • Minneapolis, Minnesota, United States

COMPLETEDNA817 miles

Mechanisms of Glucose Lowering Effect of Colesevelam HCl

NCT00596427

The mechanism by which colesevelam HCl lowers glucose is not known. Knowledge of the potential mechanism of action is important for defining the role of the drug among oral antidiabetic agents available for use in subjects with diabetes. The objective of this study is to provide insight into the mechanisms of action of colesevelam HCl in T2DM. The mechanisms of interest include hepatic insulin sensitivity, rate of appearance of exogenous glucose and changes in incretin hormone concentrations.

Carine Beysen60 participantsStarted Nov 2007

Walnut Creek, California, United States • Miami, Florida, United States • San Antonio, Texas, United States

COMPLETEDPhase 21064 miles

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

NCT01020123

The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients

Type II Diabetes Mellitus

AstraZeneca530 participantsStarted Oct 2009

Temuco, Araucania, Chile • Brentwood, TN, Chile • Santiago, Chile +74 more locations

COMPLETEDPhase 41079 miles

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment

NCT00949442

Primary Objective: To demonstrate the superiority of insulin glargine over insulin NPH (Neutral Protamin Hagedornon) the change in HbA1c from baseline to the end of the treatment period. Secondary Objective: To compare between treatment groups: * Plasma glucose (fasting, nocturnal) over time, * Changes from baseline in HbA1c over time, * Percentage of patients who reach the target of HbA1c \<7 and \<6.5, * Use of prandial insulin as rescue medication at month 6, * Incidence and rate of hypoglycemia (symptomatic diurnal and nocturnal, asymptomatic and severe), * Daily dose of insulin, * Change in body weight from baseline, * Evolution of 8-point plasma-glucose (PG) profiles, * Overall safety, * Patient reported outcomes (treatment satisfaction).

Diabetes Mellitus, Type 2

Sanofi708 participantsStarted Jul 2009

Fortaleza, Brazil • Fortaleza, Brazil • Porto Alegre, Brazil +84 more locations

COMPLETEDPhase 41357 miles

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study

NCT01121835

Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below 7% at the end of treatment and who do not experience documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) below 56 mg/dL (3.1 mmol/L)) over a 24-week treatment period, in Type 2 diabetes patients failing lifestyle management and oral agents. Secondary Objectives: To assess the effect of insulin glargine in comparison with premixed insulin on : * Evolution of HbA1c level during the treatment period Percentage of patients who reach the target of HbA1c \< 7 % and who do not experience documented symptomatic hypoglycemia confirmed by a Plasma Glucose (PG) below 70 mg/dL (3.9 mmol/L) * Percentage of patients who reach the target of HbA1c \< 6.5% and who do not experience documented symptomatic hypoglycemia confirmed by a PG below 56 mg/dL (3.1 mmol/L) \>Percentage of patients who reach the target of HbA1c \< 6.5% and who do not experience documented symptomatic hypoglycemia confirmed by a PG below 70 mg/dL (3.9 mmol/L) \>Evolution of Fasting Plasma Glucose Evolution of 7-point plasma glucose profiles * Evolution of weight * Hypoglycemia occurrence * Dose of insulins * Evolution of liver function * Overall safety

Diabetes Mellitus, Type 2

Sanofi934 participantsStarted Feb 2010

Sankt Stefan, Austria • Vienna, Austria • Vienna, Austria +93 more locations

PreviousPage 24 of 27Next

Other Conditions in Nashville

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia